Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Q2 2016
Conference Call
August 1, 2016
1© MorphoSys - Q2 2016 Conference Call
Today on the Call
© MorphoSys - Q2 2016 Conference Call
Simon Moroney
CEO
Jens Holstein
CFO
Claudia Gutjahr-Löser
Head of Corporate
Communications & IR
2
Safe Harbour
© MorphoSys - Q2 2016 Conference Call
This presentation includes forward-looking statements.
Actual results could differ materially from those included in the forward-looking statements due to
various risk factors and uncertainties including changes in business, economic competitive conditions,
regulatory reforms, foreign exchange rate fluctuations and the availability of financing.
These and other risks and uncertainties are detailed in the Company’s Annual Report.
3
MOR208 ASCO Update Phase 2a in R/R NHL
Long Duration of Responses
* Includes follicular lymphoma and other indolent NHLs. One patient with stable disease had a late response (PR) after
17 months in follow-up. This patient is not shown in the figure.
© MorphoSys - Q2 2016 Conference Call
Jurczak et al., Abstract #7545, ASCO 2016
Long-lasting responses,
up to >26 months
PFS rate:
>40% at 12 months
CR, complete response; DLBCL, diffuse large B-cell lymphoma;
NHL, non-Hodgkin’s lymphoma; PR, partial response
4
MOR208
Comprehensive Clinical Development Plan
© MorphoSys - Q2 2016 Conference Call
Indication 2016 2017 2018
NHL
DLBCL
CLL
Phase 2
Phase 2/3
IIT: Investigator-initiated trial
L-MIND: MOR208 (12mg/kg) + lenalidomide; 2nd line R/R; N=80
B-MIND: Safety evaluation expected to start soon leading into anticipated
pivotal study in 2017 to compare MOR208 (12 mg/kg) + bendamustine vs.
rituximab + bendamustine; 2nd line R/R; N~330
COSMOS: MOR208 (12mg/kg) + combo partner; BTKi-failures
MOR208 (9mg/kg) + lenalidomide; R/R, naive & Richter’s Transformation
MOR208 + ibrutinib in ibrutinib failures
MOR208
(12 mg/kg); N=92
} N=80 (Ohio State Univ. IIT)
5
MOR202
A Differentiated Antibody for Multiple Myeloma
© MorphoSys - Q2 2016 Conference Call 6
Phase 1/2a study in r/r MM – final dosing cohorts underway
MOR202 (16mg/kg)
MOR202 (16mg/kg) + Len/Dex
MOR202 (16mg/kg) + Pom/Dex
Updated data presented at ASCO 2016
Very short 2-hour infusion time with
IRRs (grades 1 & 2) in only 14% of pts.
Good responses in combo with IMiDs
2 CRs in 4 patients who were
treated per protocol in 8mg/kg
MOR202 + Pom/Dex (3rd line)
2 PRs, 1 VGPR (out of 4) in 8mg/kg
MOR202 + Len/Dex
Responses further deepening under ongoing treatment
The MOR Portfolio
5 Clinical Product Candidates, 14 Total
© MorphoSys - Q2 2016 Conference Call 7
Program Indication Target Discovery Preclinic Phase 1 Phase 2 Phase 3
Unpartnered
MOR208 DLBCLCD19
CLL
MOR202 Multiple myeloma CD38
MOR107 Fibrosis AT2-R
Immuno-oncology program
CancerMHC-associated peptides
6 Programs Various Various
Co-development & co-promotion
MOR209/ES414 (Emergent)
Prostate cancer PSMA / CD3
MOR106(Galapagos)
Inflammation Undisclosed
Immuno-oncology program(Merck Serono)
Cancer Undisclosed
Outlicensed to GSK
MOR103/GSK3196165
RA
GM-CSFOsteoarthritis of the hand
FTD, orphan status US & EU
Orphan status US & EU
Strategic Long-Term Oncology Alliance
with MD Anderson Cancer Center
© MorphoSys - Q2 2016 Conference Call
Joint identification, validation and development of novel anti-
cancer antibodies through to clinical proof-of-concept
Working on numerous targets in a variety of indications, using
MorphoSys‘s Ylanthia platform
Conducting early clinical studies
MorphoSys with option to develop antibodies in later clinical
stages in its proprietary pipeline
Complementing the parties’ drug discovery and clinical strengths, the partnership is intended to
provide access to novel targets in oncology broadening MorphoSys‘s proprietary development pipeline.
8
© MorphoSys - Q2 2016 Conference Call 9
The MorphoSys Pipeline
27 Clinical Product Candidates, 104 Total
Program/Partner Target Disease Area Discovery Preclinic Phase 1 Phase 2 Phase 3
Guselkumab (CNTO1959), Janssen IL23p19 Psoriasis
Gantenerumab, Roche Amyloid-ß Alzheimer’s disease
MOR208 CD19 ALL, CLL, NHL
MOR202 CD38 Multiple myeloma
MOR103/GSK3196165, GSK GM-CSF Inflammation
Anetumab Ravtansine (BAY94-9343), Bayer Mesothelin (ADC) Solid tumors
Bimagrumab (BYM338), Novartis ActRIIB Musculoskeletal diseases
BHQ880, Novartis DKK-1 Multiple myeloma
BPS804, Mereo/Novartis Sclerostin Brittle bone syndrome
CNTO3157, Janssen - Inflammation
CNTO6785, Janssen - Inflammation
Elgemtumab (LJM716), Novartis HER3 Cancer
Tarextumab (OMP-59R5), OncoMed Notch 2 Solid tumors
Tesidolumab (LFG316), Novartis C5 Eye diseases
VAY736, Novartis BAFF-R Inflammation
Utomilumab (PF-05082566), Pfizer 4-1BB Solid tumors
MOR209/ES414, Emergent PSMA/CD3 Prostate cancer
MOR106, Galapagos - Inflammation
BAY1093884, Bayer TFPI Hemophilia
BI–836845, BI IGF-1 Solid tumors
NOV-7, Novartis - Eye diseases
NOV-8, Novartis - Inflammation
NOV-9, Novartis - Diabetic eye diseases
NOV-10, Novartis - Cancer
NOV-11, Novartis - Blood disorders
NOV-12, Novartis - Prevention of thrombosis
Vantictumab (OMP-18R5), OncoMed Fzd 7 Solid tumors
MOR107 (LP2) AT2-R Fibrosis
Immuno-oncology program, Immatics - Cancer
Immuno-oncology program, Merck - Cancer
6 MOR programs - Various
90 Partnered Discovery Programs
13 MOR Programs
1 Outlicensed Program
Most advanced development stage
In addition, 23 partnered programs in preclinic, and 45 partnered programs in discovery
Income Statement
© MorphoSys - Q2 2016 Conference Call 10
in EUR million* 6-Months 2016 6-Months 2015
Revenues 24.3 82.6
Operating Expenses
Research and Development# 36.7 33.9
General and Administrative 6.9 7.0
Total Operating Expenses 43.5 40.9
Other Income/(Expenses) 0.1 4.4
Earnings before Interest and Taxes (EBIT) (19.2) 46.1
Finance Income/(Expenses) 0.4 1.9
Income Tax Income/(Expenses) 0.02 (11.4)
Consolidated Net Profit/(Loss) (18.8) 36.5
Diluted Net Profit/(Loss) per Share (in EUR) (0.72) 1.39
* Differences due to rounding
# Split of R&D Expenses, in EUR million 6-Months 2016 6-Months 2015
Proprietary R&D Expenses (incl. Technology Development) 28.3 25.3
Partnered Discovery Expenses 8.4 8.6
Segment Reporting
© MorphoSys - Q2 2016 Conference Call
in EUR million* 6-Months 2016 6-Months 2015
Proprietary Development
Segment Revenues 0.3 59.6
Operating Expenses 28.3 24.0
Segment EBIT (27.8) 40.2
Partnered Discovery
Segment Revenues 23.9 23.0
Operating Expenses 8.8 10.6
Segment EBIT 15.1 12.5
11
* Differences due to rounding
Balance Sheet
© MorphoSys - Q2 2016 Conference Call
in EUR million* Jun 30, 2016 Dec 31, 2015
Assets
Cash, Cash Equivalents# 67.6 90.9
Available-for-sale Financial Assets# 66.2 64.3
Bonds, Available-for-sale# 27.0 33.1
Financial Assets Classified as Loans and Receivables# 64.4 94.6
Other Current Assets 17.4 17.2
Financial Assets Classified as Loans and Receivables,
Net of Current Portion# 54.5 15.5
Other Non-current Assets 83.5 84.5
Total Assets 380.6 400.1
Liabilities & Stockholders’ Equity
Total Current Liabilities 28.9 27.5
Total Non-current Liabilities 9.2 9.9
Total Stockholders’ Equity 342.5 362.7
Total Liabilities & Stockholders’ Equity 380.6 400.1
# As of 06/30/2016, MorphoSys’s liquidity position amounted to €279.7 million (12/31/2015: €298.4 million).
12
* Differences due to rounding
Financial Guidance 2016 Re-confirmed
© MorphoSys - Q2 2016 Conference Call
in EUR million* Guidance 2016
Group Revenues 47 to 52
Proprietary R&D Expenses
(incl. Technology Development)76 to 83
EBIT -58 to -68
13
Q&A Session
Q2 2016 Conference Call
© MorphoSys - Q2 2016 Conference Call
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® , Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered
trademarks of the MorphoSys Group.
Thank You
www.morphosys.com
Corporate Communications & Investor Relations
Phone +49 (0)89 / 899 27-404
Fax +49 (0)89 / 899 27-5404
Twitter @MorphoSys
Email [email protected]